Patheon’s Post

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3KbQEOm While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3KbQEOm

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3V6gqd4 While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3V6gqd4

#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer

Hope to see you there! My colleagues Pouria Motevalian and Amy Lavelle will be presenting on these hot topics - scaling up gene therapy processes & analytical strategy #asgct2024

Transduction of cells with lentiviruses has not been as convenient and uncomplicated as it can be with the use of Takara Lenti-X Transduction Sponge! The process involves simply adding a mixture of virus and cells onto the sponge and allowing for incubation. The sponge acts as a microfluidic transduction enhancer, bringing cells and viruses in close proximity during incubation and then dissolving upon subsequent centrifugation. As a result, the efficiency of transduction is enhanced with a more convenient and user-friendly method. For more info check related Takara Bio Europe webpages: https://lnkd.in/dwxNmfDb https://lnkd.in/dYr5N7Xc Contact us: info@gen-era.com.tr #lentivirus #transduction #Takara #LentiX #sponge #microfluidic

Are you going to the American Society of Gene & Cell Therapy (#ASGCT) 27th Annual Meeting in #Baltimore, Maryland from May 7-11? If so, be sure to attend Thermo Fisher Scientific's sponsored session on Friday, May 10 at 8 a.m. EDT: “Revolutionizing #genetherapy services: A synergistic approach to analytics and scaling up through CDMO-CRO collaboration.” This session will explore the possibilities of adeno-associated viral (#AAV) vectors as widely-used carriers for #genetherapy medicinal products (#GTMPs). It will also discuss the challenges in #scalability and #analytics during AAV production that may limit their impact. Additionally, it will cover how strategic CDMO-CRO collaborations can help address these hurdles. Learn more about this sponsored session here: http://spr.ly/6044brBXa